Nicole Daley is a partner in Goodwin’s Life Sciences group. Ms. Daley’s practice spans the entire corporate life cycle for privately held and publicly traded companies in the life sciences industry, including startup and formation matters, corporate governance, venture capital financings, mergers and acquisitions, joint ventures and collaborations, capital markets transactions, SEC reporting and disclosures, and corporate reorganizations.





Ms. Daley’s recent client representations include the following:

IPOs and Capital Markets Transactions

  • Esperion Therapeutics in its $280 million 144A offering, $250 million “at-the-market” offering, and $225 million follow-on public offering.
  • Bluebird bio in its $75 million private placement financing.
  • AlloVir in its $317.7 million initial public offering and $100 million “at-the-market” offering. 
  • Cerevel Therapeutics in its $350 million follow-on public offering.
  • Kymera Therapeutics in its $257 million follow-on public offering.
  • The underwriters in connection with Krystal Biotech’s over $250 million of follow-on public offerings.
  • Achilles Therapeutics (United Kingdom) in its $175.5 initial public offering. 
  • Deciphera Pharmaceuticals in its $175 million follow-on public offering and $200 million “at-the-market” offering.
  • Karuna Therapeutics in its $100 million initial public offering, $250 million and $287.5 million follow-on public offerings, and $150 million “at-the-market” offering.
  • BioDelivery Sciences International in its $60 million follow-on public offering. 
  • Alnylam Pharmaceuticals in a $387.5 million follow-on public offering.

Private Company Financing Transactions

  • Beta Bionics in its $63 million Series B2 financing and its $57 million Series C financing.
  • Versanis Bio in its $70 million Series A financing.
  • OrbiMed as co-lead investor in the $40 million Series A financing of Gennao Bio.
  • Amylyx Pharmaceuticals in its $135 million Series C financing.
  • Imvaq Therapeutics in its $15 million Series B Preferred Stock and convertible note financing. 
  • Karuna Therapeutics in its $82 million Series B financing.
  • Thrive Earlier Detection Corp. in its $110 million Series A financing.

Joint Ventures, M&A and Collaborations

  • Vaccitech plc in its acquisition of Avidea Technologies, Inc. for approximately $40 million in cash and equity, plus potential payments upon achievement of milestones.
  • Plug Power in a $1.5 billion equity investment in connection with its strategic partnership with South Korea-based SK Group.
  • Thrive Earlier Detection Corp. in its acquisition by Exact Sciences Corporation for up to $2.15 billion.
  • Unum Therapeutics in the sale of its BOXR (Bolt-on Chimeric Receptor) technology for approximately $11.5 million.
  • Unum Therapeutics in its acquisition of Kiq LLC, a privately held, biotechnology company focused on the discovery and development of precision kinase inhibitors, and concurrent PIPE investment to raise $104 million.
  • Avadel Legacy Pharmaceuticals, a wholly-owned subsidiary of Avadel Pharmaceuticals (Ireland), in the sale of its hospital product assets for approximately $40 million.
  • Alnylam Pharmaceuticals in a $100 million equity financing closed in connection with its $2 billion strategic financing collaboration with Blackstone.
  • CRISPR Therapeutics in a series of transactions by which CRISPR acquired 100% of the partnership interests of Casebia Therapeutics.
  • BeiGene in its $2.7 billion share sale as part of a global strategic collaboration with Amgen.
  • BlueRock Therapeutics on its agreement to be fully acquired by Bayer AG for up to $1 billion.
  • Ultragenyx Pharmaceutical Inc. on its partnership with GeneTx Biotherapeutics LLC to develop GeneTx’s GTX-102.
  • Arvinas, Inc. in its collaboration with Bayer to jointly launch a new company to leverage Arvinas’ PROTAC technology for agricultural applications.
  • Alnylam Pharmaceuticals in a $400 million equity financing closed in connection with Alnylam’s collaboration with Regeneron Pharmaceuticals.
Professional Activities

Ms. Daley serves on the Board of Directors of Women in the Enterprise of Science and Technology (WEST), a Boston-based nonprofit organization that provides a powerful forum and supportive environment for early and mid-career women in the fields of science and technology. She is also a contributor and editor of Big Molecule Watch, the firm’s award-winning blog that reports real-time analysis and updates on regulatory issues, litigation, legislation and other news in the developing world of biosimilars. Ms. Daley is a member of the Boston Bar Association and the Navajo Nation Bar Association.

Professional Experience

Prior to joining Goodwin, Ms. Daley was Of Counsel in the Corporate group at DLA Piper in Boston. Earlier in her career, she was an associate in the Corporate practices at DLA Piper and Squire Patton Boggs in Phoenix, and Gunderson Dettmer in Boston. Ms. Daley also previously served as Associate General Counsel of a Nasdaq-listed global provider of telecom business solutions, handling corporate governance matters and Exchange Act reporting, subsidiary maintenance, and litigation management and case strategy.

In The News









J.D., 2005
Boston College Law School
B.A., 2002
Dartmouth College
(summa cum laude)



Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique